发现潜在的药物向阿尔茨海默病关键基因的发现:从转录组分析和分子对接的见解
Hanjie Liu1, Hui Yang2, Maochun You1
1Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, Sichuan, China.
Journal of molecular neuroscience : MN
|May 27, 2024
概括
研究人员确定了与阿尔茨海默病 (AD) 相关的关键基因,并发现二甲可能针对这些基因. 这表明,通过调节免疫和炎症反应,对阿尔茨海默病提出了潜在的新疗法战略.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默氏症 (AD) 是一个主要的全球健康问题.
- 确定阿尔茨海默病的治疗点至关重要.
研究的目的:
- 在阿尔茨海默病中识别关键基因和潜在的药物标.
- 探索候选药物对已识别的标的治疗潜力.
主要方法:
- 在阿兹海默症患者中分析了来自人类大脑前皮层的单核转录组数据.
- 对差异表达基因 (DEGs) 的查,基因本体学 (GO) 分析,KEGG通路丰富和蛋白质-蛋白质相互作用 (PPI) 网络分析.
- 分子对接和动力学模拟以评估药物标结合.
主要成果:
- 564个DEG被确定,其中ISG15,STAT1,MX1,IFIT3,IFIT2,RSAD2,IFIT1,IFI44,IFI44L和DDX58被确定为枢纽基因.
- 丰富分析突出了与病毒反应,IFN-γ信号传递和病毒感染相关的途径.
- 狄克洛菲纳克证明与IFI44和IFI44L有良好的结合.
结论:
- 候选药物可能针对关键基因来调节病毒反应和IFN-γ信号通路.
- 潜在的治疗机制包括抗病毒作用,免疫平衡的改善和减少抗老年治疗的炎症.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.8K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.0K
相关概念视频
01:26Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
01:22Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180